Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling
The FEBS Journal · 2024
DOI: 10.1111/febs.17196 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Matteo Costacurta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Monash Haematology, Monash Health, Clayton, Australia. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Ubiquitin-Protein Ligases, Bortezomib. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Family of Mr Lawrence Bode, National Health and Medical Research Council, Monash Haematology Research Grant.
Abstract (Originalsprache)
Immunomodulatory imide drugs (IMiDs) are central components of therapy for multiple myeloma (MM). IMiDs bind cereblon (CRBN), an adaptor for the CUL4‐DDB1‐RBX1 E3 ligase to change its substrate specificity and induce degradation of ‘neosubstrate’ transcription factors that are essential to MM cells. Mechanistic studies to date have largely focussed on mediators of therapeutic activity and insight into clinical IMiD toxicities is less developed. We adopted BioID2‐dependent proximity labelling (BioID2‐CRBN) to characterise the CRBN interactome in the presence and absence of various IMiDs and the proteasome inhibitor, bortezomib. We aimed to leverage this technology to further map CRBN interactions beyond what has been achieved by conventional proteomic techniques. In support of this approach, analysis of cells expressing BioID2‐CRBN following IMiD treatment displayed biotinylation of known CRBN interactors and neosubstrates. We observed that bortezomib alone significantly modifies the CRBN interactome. Proximity labelling also suggested that IMiDs augment the interaction between CRBN and proteins that are not degraded, thus designating ‘neointeractors’ distinct from previously disclosed ‘neosubstrates’. Here we identify Non‐Muscle Myosin Heavy Chain IIA (MYH9) as a putative CRBN neointeractor that may contribute to the haematological toxicity of IMiDs. These studies provide proof of concept for proximity labelling technologies in the mechanistic profiling of IMiDs and related E3‐ligase‐modulating drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Haematology, Monash Health, Clayton, Australia.
- Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
- The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
- Department of Medical Biology, The University of Melbourne, Parkville, Australia.
- Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
ORCID-Profile: Jake Shortt
Förderung
- Family of Mr Lawrence Bode
- National Health and Medical Research Council
- Monash Haematology Research Grant
Zitieren
APA
Costacurta, M., Sandow, J. J., Maher, B., Susanto, O., Vervoort, S. J., Devlin, J. R., Garama, D., Condina, M. R., Steele, J. R., Kahrood, H. V., Gough, D., Johnstone, R. W., & Shortt, J. (2024). Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling. The FEBS Journal. https://doi.org/10.1111/febs.17196
Vancouver
Costacurta M, Sandow JJ, Maher B, Susanto O, Vervoort SJ, Devlin JR, et al. Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling. The FEBS Journal. 2024. doi:10.1111/febs.17196
BibTeX
@article{Costacurta2024,
author = {Costacurta, Matteo and Sandow, Jarrod J and Maher, Belinda and Susanto, Olivia and Vervoort, Stephin J and Devlin, Jennifer R and Garama, Daniel and Condina, Mark R and Steele, Joel R and Kahrood, Hossein V and Gough, Daniel and Johnstone, Ricky W and Shortt, Jake},
title = {Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17196}
}
EUVIMED